Overview

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Status:
Not yet recruiting

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

Phase:

Phase 1

Details

Lead Sponsor:

Yale University

Treatments:

Amiloride
Bendroflumethiazide